National Cancer Institute (NCI): Phase 1 study started recruiting, 36 planned (Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8)
National Cancer Institute (NCI): Phase 1 study started recruiting, 36 planned (Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8). Its enrollment of 36 is below the median of 80 (23rd percentile). Dated 20 days ago, it is in the active follow-up window. Score 35/100. As of 2026-11-05, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 36 · 23th percentile of 9,177 ClinicalTrialStartPulse records · 0.5x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related US ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | National Cancer Institute (NCI) |
| Sponsor type | NIH |
| Study | Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer |
| NCT ID | NCT07137416 |
| Phase | Phase 1 |
| Status | recruiting |
| Conditions | Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Metastatic HER2-Low Breast Carcinoma |
| Intervention types | procedure, drug, biological |
| Target enrollment | 36 |
| Site countries | United States |
| Posted | 2025-08-22 |
| Planned start | 2026-10-06 |
| Event | Started recruiting |
| Event date | 2026-10-06 |
| Last update posted | 2026-10-16 |
| enrollment percentile | 23th of 9,177 (median 80, 0.5x median) |
| Peer records CSV (500 US records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch National Cancer Institute (NCI)
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of US records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock National Cancer Institute (NCI) + 500 US peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-16
- Data refreshed: 2026-11-05
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (US first): Sanofi · Pfizer · National Institute of Arthritis and Musculoskeletal and Skin · Apple Inc. · National Cancer Institute (NCI) · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Thu, 05 Nov 2026 08:46:16 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: National Cancer Institute (NCI) and 2,595 US peers
- US ClinicalTrialStartPulse records like this one: 2,595
- National Cancer Institute (NCI)'s enrollment: 23rd percentile of 9,177 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every US peer: $519,000 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
35 / 100 Score
- Just started recruiting: sites, recruitment and supply are active.
What is the ClinicalTrialStartPulse record for National Cancer Institute (NCI)?
National Cancer Institute (NCI)'s Phase 1 study (NCT07137416) in Anatomic Stage III Breast Cancer AJCC v8, first posted 2025-08-22: started recruiting (2026-10-06), in an update posted 2026-10-16.
How does National Cancer Institute (NCI) compare to other ClinicalTrialStartPulse records?
Its enrollment of 36 is below the median (23th percentile); smaller records often move faster and face less competition. It is 20 days old, still within a typical 45-day follow-up window. Its Score of 35/100 is modest; treat it as background rather than a priority.
National Cancer Institute (NCI) vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| National Cancer Institute (NCI) | US | 36 | 23rd | 2026-10-16 |
| Eli Lilly and Company | US | 108 | 62nd | 2026-11-04 |
| AbbVie | US | 135 | 68th | 2026-11-04 |
| Janssen Research & Development, LLC | US | 144 | 69th | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Phase 1 ClinicalTrialStartPulse: United States sites
More US public-record feeds
U.S. DOT Injury/Illness Summary Pulse in US U.S. DOT FRA Regulated Mode Major Security Events Pulse in US U.S. DOT Crossing Inventory Data Pulse in US U.S. DOT Insur - All With History Pulse in US USAC Telecom CAF Locations Obligation and Deployment by Speed Tier Data Pul in US U.S. CDC 2022 Final Assisted Reproductive Technology Summary Pulse in US U.S. DOT Rail Equipment Accident/Incident Data Subset Pulse in US U.S. DOT Monthly Modal Time Series Pulse in US
How to monitor National Cancer Institute (NCI) and peer phase 1 records
Get new ClinicalTrialStartPulse records like National Cancer Institute (NCI) by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.